Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, announced the close of a $95 million Series B financing. The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, RiverVest, and US Venture Partners. In conjunction with the financing, Zach Scheiner from RA and Nanna Luneborg from Forbion have joined Sparrow's Board of Directors.